Non-Small Cell Lung Cancer

EQRx Inc (NASDAQ: EQRX) announced the presentation of updated data from the Phase 3 GEMSTONE-301 trial of sugemalimab in non-small cell lung cancer (NSCLC). As of the March data cutoff, the final progression-free survival (PFS) analysis showed that sugemalimab continued to...

Athenex Inc (NASDAQ: ATNX) announced a clinical trial collaboration and supply agreement with Merck Co & Inc (NYSE: MRK).  The agreement applies to the expansion phase of the Phase 1 clinical trial evaluating Athenex's oral paclitaxel combined with Merck's...

Bristol Myers Squibb Co (NYSE: BMY) announced results from the Phase 3 CheckMate -816 trial in resectable non-small cell lung cancer (NSCLC). The data showed that neoadjuvant treatment with three Opdivo (nivolumab) cycles combined with chemotherapy significantly improved event-free...

Eli Lilly And Co (NYSE: LLY) announced updated data from the Phase 1/2 LIBRETTO-001 trial of Retevmo (selpercatinib) in patients with RET fusion-positive non-small cell lung cancer (NSCLC).  The updated analysis utilized a June 15, 2021, data cut-off. Among 247...

Immutep Limited (NASDAQ: IMMP) has announced new interim data from the Phase 2 TACTI002 trial of eftilagimod alpha (efti or IMP321), combined with Merck & Co Inc's Keytruda (pembrolizumab). The trial included 36 patients with PD-L1 unselected 2nd line PD-X...

Cullinan Oncology Inc (NASDAQ: CGEM) announced clinical and regulatory updates from Phase 1/2a trial of CLN-081 in a non-small cell lung cancer (NSCLC) setting. The trial includes NSCLC patients harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations progressed...

Merck & Co Inc (NYSE: MRK) announced results from the Phase 3 KEYNOTE-091 trial evaluating Keytruda compared to placebo for adjuvant treatment of non-small cell lung cancer (NSCLC). The trial included patients with stage IB (≥4 centimeters) to IIIA NSCLC following surgical resection (...

The FDA has signed off Iovance Biotherapeutics Inc's (NASDAQ: IOVA) Investigational New Drug Application (IND) first genetically modified TIL therapy, IOV-4001, for unresectable or metastatic melanoma and stage III or IV non-small-cell lung cancer (NSCLC). IOV-4001 leverages the...

Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc (NASDAQ: CHRS) have shared biomarker analyses from the CHOICE-01 Phase 3 trial of toripalimab plus chemotherapy as first-line treatment of advanced squamous or non-squamous non-small cell lung cancer (NSCLC)....

BioNTech SE (NASDAQ: BNTX) has expanded its strategic collaboration with Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to its FixVac candidate BNT116 combined with Libtayo (cemiplimab) in advanced non-small-cell lung cancer (NSCLC).  Under the terms of the agreement,...

Spectrum Pharmaceuticals Inc (NASDAQ: SPPI) announced the presentation of safety and efficacy results from Cohort 4 of the ZENITH20 trial evaluating poziotinib in various non-small cell lung cancer settings. The data comes from 70 first-line patients with non-small lung cancer (...

The FDA has approved Bristol Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab) in combination with platinum-doublet chemotherapy for resectable non-small cell lung cancer (NSCLC) in the neoadjuvant setting. The agency approved the Opdivo combo just five days after accepting...

The FDA has accepted for review Mirati Therapeutics Inc's (NASDAQ: MRTX) marketing application seeking approval for adagrasib for non-small cell lung cancer (NSCLC). The application covers NSCLC patients harboring the KRASG12C mutation who have received at least one prior...

The European Commission has approved Pfizer Inc's (NYSE: PFE) Lorviqua (lorlatinib) for a form of advanced non-small-cell lung cancer (NSCLC). Lorlatinib is available in the U.S. under the brand name Lorbrena. The approval covers lorlatinib as monotherapy for anaplastic lymphoma...

Amgen Inc's (NASDAQ: AMGN) Lumakras (sotorasib) has been approved in Japan for KRAS G12C-mutated positive, unresectable, advanced and/or recurrent non-small cell lung cancer (NSCLC) progressed after systemic anticancer therapy. Lumakras is now approved in nearly 40 countries....